Results
1 -
10 of
92Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge, Annals of Hematology Granulocyte colony-stimulating factor potentiates all-trans retinoic acid-induced granulocytic differentiation in acute promyelocytic leukemia cell line HT93A, Cancer Cell International Regulation of macrophage-mediated chronic inflammation by JAK inhibitors, Arthritis Research & Therapy Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study, Annals of Hematology A Critical Review of the Role and Limitations of JAK Inhibitors in Myelofibrosis Therapy, Myeloproliferative Neoplasms Ruxolitinib, Small Molecules in Oncology The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseases, International Journal of Hematology Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report, BMC Research Notes Research Pipeline I: Topical Therapies, Advances in Psoriasis